This is an original research article on uptake, timing and efficacy of bilateral risk reducing surgery (RRM and RRSO) in 887  female BRCA1/BRCA2 carriers unaffected by cancer at testing. This is one of the largest prospective cohorts, covering both surgeries, published to date. More than 50% of women in the study underwent RRM and more than 75% underwent RRSO. Even though both risk reducing surgeries showed a significant effect on relevant cancer risk reduction, we believe that the timing is still suboptimal. We found no statistically significant RRSO protective effect on breast cancer, which is in keeping with other recent publications on this topic. (By Dr. Ruta Marcinkute, https://jmg.bmj.com/content/early/2021/02/09/jmedgenet-2020-107356 )